AARTIPHARM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 24/100 — Quality 50 · Valuation 4 · Momentum 0
| Share price | ₹697.95 |
| Market cap | ₹6,433 Cr |
| P/E ratio | 36.9 |
| P/B ratio | 3.0 |
| ROCE | 11.0% |
| Dividend yield | 0.56% |
| Book value | ₹234.28 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,819 Cr | ₹175 Cr | 20.0% |
| 2025 | ₹2,115 Cr | ₹272 Cr | 22.0% |
| 2024 | ₹1,853 Cr | ₹217 Cr | 21.0% |
| 2023 | ₹1,945 Cr | ₹193 Cr | 18.0% |
| 2022 | ₹1,200 Cr | ₹122 Cr | 17.0% |
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for d